MeMed Welcomes Three New Advisory Board Members

MeMed has added three experts to its advisory board: Beat Müller, M.D., Dave Hickey, and David Shulkin, M.D. The trio’s decades of experience in medicine, industry, and healthcare policy strengthen the company’s work in host-response technologies, which combine machine learning with rapid immune response measurements to improve infectious disease care.

“We are privileged to work alongside such an extraordinary group of leaders,” MeMed Co-Founder/CEO Eran Eden, Ph.D., said. “Their expertise will help us advance the field of host-response diagnostics and bring these tools to clinicians and patients worldwide.”

Dr. Müller is a professor of Medicine at the University of Basel and a global authority on procalcitonin diagnostics and sepsis care. “AMR and sepsis are deeply interconnected challenges, and host-response diagnostics are the next frontier in addressing them. I look forward to working with MeMed to further strengthen clinical outcome data for their FDA-cleared MeMed BV test and the in-development FDA Breakthrough-designated MeMed Severity test,” Dr. Müller said. “These tools have the potential to significantly improve clinical decision-making by providing actionable insights into bacterial versus viral infections and predicting the likelihood of suspected sepsis severity.”

Hickey, is the former executive vice president and president of BD’s Life Sciences segment and a seasoned in-vitro diagnostics (IVD) expert. “Integrating traditional IVD with host-response and machine learning is a major step forward. MeMed’s approach is expected to enhance patient management throughout the sepsis continuum of care, addressing unmet needs in both centralized hospital labs and decentralized settings,” he stated. “I am excited to help shape their commercial strategy and expand partnerships to make these innovations widely accessible and make sure they impact as many patients as possible.”

Dr. Shulkin is the ninth Secretary of the U.S. Department of Veterans Affairs and board member at Sanford Health. He has significant expertise in U.S. healthcare delivery and policy. “Sepsis and AMR are among the most pressing challenges in U.S. healthcare,” he commented. “MeMed’s host-response solutions have the potential to revolutionize care delivery, reduce unnecessary antibiotic use, and optimize resources in a cost-effective way. I look forward to helping operationalize them to address these critical needs.”

MeMed BV and MeMed Key are cleared by the U.S. Food and Drug Administration (FDA), CE-IVD (IVDR certified) and available in the United States and European Union. MeMed Severity is currently in development and has not been cleared for sale by any regulatory authority.

MeMed is working to translate the immune system’s complex signals into simple insights that transform the way diseases are diagnosed and treated. MeMed BV is the first FDA-cleared host-immune response test for accurately distinguishing between bacterial and viral infections in 15 minutes. MeMed Severity is a host-response test designed to predict the likelihood of progression to severe outcomes in patients with suspected acute infection or sepsis.